FMP
IDEAYA Biosciences, Inc.
IDYA
NASDAQ
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
23.14 USD
-0.01 (-0.04322%)
2023
2022
2021
2020
23.39M
50.93M
27.94M
19.54M
4.01M
2.1M
1.73M
39.7M
19.38M
48.83M
26.22M
-20.16M
157.81M
113.43M
78.21M
54.88M
129.51M
89.54M
58.16M
39.7M
28.31M
23.9M
20.05M
15.18M
0
0
0
0
28.31M
23.9M
20.05M
15.18M
0
0
0
0
-134.43M
-62.5M
-50.27M
-35.34M
21.47M
3.85M
506k
849k
-112.96M
-58.66M
-49.76M
-34.49M
0
-3.85M
-2.23M
-2.23M
-112.96M
-54.81M
-47.53M
-32.27M
-1.96
-1.32
-1.35
-1.31
-1.96
-1.32
-1.35
-1.31
57.52M
41.44M
35.25M
24.72M
57.52M
41.44M
35.25M
24.72M
-130.42M
-60.4M
-48.54M
-33.96M
2023
2022
2021
2020
-235.4M
-176.75M
-126.99M
-92.49M
-112.96M
-54.81M
-47.53M
-32.27M
0
0
0
0
0
0
0
0
-348.36M
-235.4M
-176.75M
-126.99M
-112.96M
-58.66M
-49.76M
-34.49M
2023
2022
2021
2020
8.41M
8.99M
8.66M
9.48M
4.01M
2.1M
1.73M
1.38M
-2.37M
-3.44M
-2.64M
-493k
6.77M
10.34M
9.58M
8.59M
2023
2022
2021
2020
0
0
0
0
0
0
0
0
0
0
0
0
All figures are in USD.